HK1209732A1 - Compound as wnt signaling inhibitor, composition, and use thereof wnt - Google Patents
Compound as wnt signaling inhibitor, composition, and use thereof wntInfo
- Publication number
- HK1209732A1 HK1209732A1 HK15110400.6A HK15110400A HK1209732A1 HK 1209732 A1 HK1209732 A1 HK 1209732A1 HK 15110400 A HK15110400 A HK 15110400A HK 1209732 A1 HK1209732 A1 HK 1209732A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- wnt
- compound
- composition
- signaling inhibitor
- wnt signaling
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/077032 WO2013185353A1 (en) | 2012-06-15 | 2012-06-15 | Compound as wnt signaling inhibitor, composition, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209732A1 true HK1209732A1 (en) | 2016-04-08 |
Family
ID=49757457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110400.6A HK1209732A1 (en) | 2012-06-15 | 2015-10-22 | Compound as wnt signaling inhibitor, composition, and use thereof wnt |
Country Status (16)
Country | Link |
---|---|
US (2) | US9556144B2 (es) |
EP (1) | EP2861590B1 (es) |
JP (1) | JP6081582B2 (es) |
KR (1) | KR101824300B1 (es) |
CN (2) | CN104379583B (es) |
AU (1) | AU2012382875B2 (es) |
BR (1) | BR112014031263B1 (es) |
CA (1) | CA2875372C (es) |
ES (1) | ES2649673T3 (es) |
HK (1) | HK1209732A1 (es) |
IL (1) | IL236242B (es) |
IN (1) | IN2015DN00129A (es) |
MX (1) | MX359146B (es) |
RU (1) | RU2627712C2 (es) |
SG (1) | SG11201408237YA (es) |
WO (1) | WO2013185353A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2686347T3 (en) | 2011-03-16 | 2018-06-25 | Argenx Bvba | Antibodies against CD70 |
SG11201408237YA (en) | 2012-06-15 | 2015-01-29 | Curegenix Inc | Compound as wnt signaling inhibitor, composition, and use thereof |
CA2905830C (en) | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of cancer |
AU2014244506A1 (en) | 2013-03-14 | 2015-09-17 | Curegenix, Inc. | Compounds for treatment of fibrosis diseases |
CN105348298B (zh) * | 2014-07-04 | 2019-03-19 | 沈阳中化农药化工研发有限公司 | 取代芳基吡啶类化合物及其用途 |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
CA2985818A1 (en) * | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy |
CN107759584B (zh) * | 2016-08-16 | 2021-06-01 | 苏州云轩医药科技有限公司 | 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用 |
WO2017167150A1 (zh) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | 一种3-氟吡啶杂环化合物及其应用 |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
BR112019018093A2 (pt) * | 2017-03-30 | 2020-06-16 | F. Hoffmann-La Roche Ag | Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto |
CN107510652B (zh) * | 2017-07-21 | 2018-07-13 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
UY38511A (es) | 2018-12-18 | 2020-07-31 | Argenx Bvba | Terapia de combinación cd70 |
WO2021224409A1 (en) | 2020-05-06 | 2021-11-11 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
CN117088876A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8908229D0 (en) | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
WO2004043925A2 (en) * | 2002-11-08 | 2004-05-27 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
RU2007130077A (ru) * | 2005-01-07 | 2009-02-20 | Эмори Юниверсити (Us) | Антагонисты cxcr4 и их применение для лечения вич-инфекции |
RU2467007C2 (ru) * | 2005-12-21 | 2012-11-20 | Эбботт Лэборетриз | Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv |
US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
WO2008086462A2 (en) | 2007-01-11 | 2008-07-17 | Wyeth | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS |
EP2576540B1 (en) * | 2010-05-26 | 2019-09-04 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
SG11201408237YA (en) | 2012-06-15 | 2015-01-29 | Curegenix Inc | Compound as wnt signaling inhibitor, composition, and use thereof |
CA2905830C (en) * | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of cancer |
AU2014244506A1 (en) * | 2013-03-14 | 2015-09-17 | Curegenix, Inc. | Compounds for treatment of fibrosis diseases |
-
2012
- 2012-06-15 SG SG11201408237YA patent/SG11201408237YA/en unknown
- 2012-06-15 CN CN201280073873.4A patent/CN104379583B/zh active Active
- 2012-06-15 EP EP12878945.0A patent/EP2861590B1/en active Active
- 2012-06-15 US US14/408,254 patent/US9556144B2/en active Active
- 2012-06-15 ES ES12878945.0T patent/ES2649673T3/es active Active
- 2012-06-15 AU AU2012382875A patent/AU2012382875B2/en active Active
- 2012-06-15 KR KR1020147034377A patent/KR101824300B1/ko active IP Right Grant
- 2012-06-15 CN CN201610534447.6A patent/CN106188045B/zh active Active
- 2012-06-15 RU RU2014150338A patent/RU2627712C2/ru active
- 2012-06-15 WO PCT/CN2012/077032 patent/WO2013185353A1/en active Application Filing
- 2012-06-15 JP JP2015516405A patent/JP6081582B2/ja active Active
- 2012-06-15 BR BR112014031263-0A patent/BR112014031263B1/pt active IP Right Grant
- 2012-06-15 MX MX2014015281A patent/MX359146B/es active IP Right Grant
- 2012-06-15 CA CA2875372A patent/CA2875372C/en active Active
-
2014
- 2014-12-14 IL IL236242A patent/IL236242B/en active IP Right Grant
-
2015
- 2015-01-06 IN IN129DEN2015 patent/IN2015DN00129A/en unknown
- 2015-10-22 HK HK15110400.6A patent/HK1209732A1/xx unknown
-
2016
- 2016-11-23 US US15/359,900 patent/US10087181B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2014015281A (es) | 2015-06-23 |
BR112014031263B1 (pt) | 2022-03-29 |
EP2861590A4 (en) | 2015-12-30 |
CA2875372C (en) | 2019-04-09 |
JP2015523348A (ja) | 2015-08-13 |
AU2012382875B2 (en) | 2017-04-20 |
WO2013185353A1 (en) | 2013-12-19 |
CN104379583B (zh) | 2016-06-08 |
EP2861590A1 (en) | 2015-04-22 |
RU2014150338A (ru) | 2016-08-10 |
MX359146B (es) | 2018-09-17 |
CN104379583A (zh) | 2015-02-25 |
KR20150024826A (ko) | 2015-03-09 |
RU2627712C2 (ru) | 2017-08-10 |
CA2875372A1 (en) | 2013-12-19 |
JP6081582B2 (ja) | 2017-02-15 |
CN106188045A (zh) | 2016-12-07 |
KR101824300B1 (ko) | 2018-01-31 |
IN2015DN00129A (es) | 2015-05-29 |
US20170073344A1 (en) | 2017-03-16 |
US20150119387A1 (en) | 2015-04-30 |
IL236242A0 (en) | 2015-02-01 |
BR112014031263A2 (pt) | 2018-04-24 |
NZ702413A (en) | 2016-08-26 |
CN106188045B (zh) | 2018-01-16 |
IL236242B (en) | 2018-04-30 |
SG11201408237YA (en) | 2015-01-29 |
ES2649673T3 (es) | 2018-01-15 |
US9556144B2 (en) | 2017-01-31 |
EP2861590B1 (en) | 2017-10-25 |
US10087181B2 (en) | 2018-10-02 |
AU2012382875A1 (en) | 2014-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209732A1 (en) | Compound as wnt signaling inhibitor, composition, and use thereof wnt | |
IL238958A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
IL238959A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
HUE044300T2 (hu) | 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk | |
IL235155B (en) | Arginase inhibitor compounds, compositions comprising same and uses thereof | |
HK1205513A1 (en) | Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals | |
EP2968357A4 (en) | S-IMINO-S-OXO IMINOTHIAZINE COMPOUNDS AS INHIBITORS OF THE SITE SS CLEAVING ENZYME OF THE APP, COMPOSITIONS, AND USE THEREOF | |
EP2968356A4 (en) | S-IMINO-S-OXO IMINOTHIADIAZINE COMPOUNDS AS APP-SITE CLEAVING ENZYME INHIBITORS, COMPOSITIONS, AND USE THEREOF | |
HK1216250A1 (zh) | '- '-羥基-二氫麥角胺化合物及組合物 | |
ZA201404065B (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
HK1201270A1 (en) | Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5-- | |
IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
IL280316B (en) | Amphiphilic compounds, preparations and their use | |
IL237542B (en) | Amphiphilic compounds, their preparations and uses | |
IL237540B (en) | Amphiphilic compounds, their preparations and uses | |
IL237538A0 (en) | Amphiphilic compounds, their preparations and uses | |
PL2740807T3 (pl) | Kompozycja syntetycznego płynu hartowniczego | |
IL237539A0 (en) | Amphiphilic compounds, their preparations and uses | |
EP3028703A4 (en) | Wnt SIGNALING INHIBITOR | |
IL232620B (en) | Tricyclic compounds, preparations including them and their use | |
GB201206998D0 (en) | New compound and uses | |
GB201112092D0 (en) | Intumescent composition |